How is AICAR dosed and mixed?
10 mg of AICAR from a 100 mg vial mixed with 5 mL is 50 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 2 mL of water | 5 mL of water |
|---|---|---|
| 50 mg | 25 mg/mL: 5 mg is 20 units, 10 mg is 40 units | 10 mg/mL: 5 mg is 50 units, 10 mg is 100 units |
| 100 mg | 50 mg/mL: 5 mg is 10 units, 10 mg is 20 units | 20 mg/mL: 5 mg is 25 units, 10 mg is 50 units |
Searches returned no label or approved dose for AICAR; in bypass surgery, the McSPI trial (1995, 633 patients) gave acadesine by intravenous infusion at 0.05 or 0.1 mg.kg-1.min-1 for 7 h against placebo, and searches found no human trial of a subcutaneous or injected-vial dose.1
Mixing a powder and reading syringe units
Searches returned no vial strength, mixing volume or fixed mg dose for AICAR, so the vial sizes, water volumes and doses in the table, the worked example and the calculator are example numbers for unit arithmetic only, not figures from any source. The only preparation a source describes is the RED-CABG registry entry's infusion: acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, run over about 7 hours at 0.1 mg/kg/min (1.2 mL/min for a 500 mL solution).2
10 mg of AICAR from a 100 mg vial mixed with 5 mL is 50 units on a U-100 syringe.
10 mg of AICAR from a 100 mg vial mixed with 5 mL is 50 units on a U-100 syringe.
What the trials gave
Searches returned no label or approved dose, and an EMA orphan designation is not a marketing authorisation.3 In the trials below, doses were weight-based and given by intravenous infusion, with one study in healthy men also giving an oral solution, and doses differed by trial and indication.1456
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| McSPI (1995) | Placebo (n = 212), 0.05 mg.kg-1.min-1 (n = 214) or 0.1 mg.kg-1.min-1 (n = 207) by intravenous infusion, starting 15 min before anesthetic induction1 | 633 patients undergoing CABG surgery1 | 7 h |
| RED-CABG (Newman, 2012) | 0.1 mg/kg per minute by intravenous infusion, or placebo, beginning just before anesthesia induction7 | 3080 participants having CABG surgery, randomized of a planned 7500 before the trial was stopped for futility7 | 7 hours |
| CLL phase I/II (Van Den Neste) | Part I: single doses of 50 to 315 mg/kg; Part II: 210 mg/kg on Days 1 and 4, or on Days 1, 4, 8, 11 and 15; by intravenous infusion5 | Twenty-four patients with relapsed/refractory CLL: eighteen in Part I, six in Part II5 | 4-h infusion |
| Healthy-men study (Dixon, 1991) | 10, 25, 50 or 100 mg/kg, orally and intravenously, or placebo6 | Healthy men: four on active drug and two on placebo at each dose level6 | 1-week wash-out between the IV and oral doses |
| Babraj (2009) | 10 or 20 mg·kg−1·h−1 by intravenous infusion4 | Six healthy young subjects, eight older subjects and eight subjects with type 2 diabetes4 | From 3 to 6 h of a 6-h infusion study |
| Bosselaar (2011) | 67 mg·kg(-1) intravenously, or placebo (saline), during euglycemic hyperinsulinemic clamps8 | Ten healthy participants8 | Last 60 minutes of a 120-minute clamp |
Storage
Searches returned no storage or stability conditions for AICAR, before or after mixing.
Frequently asked questions
What safety findings did the human trials report?
In the McSPI trial, adverse events were similar between acadesine and placebo, except that serum uric acid rose transiently on the high dose.1 In the CLL phase I/II study (Van Den Neste; twenty-four patients with relapsed/refractory CLL), grade 2 or higher hyperuricaemia occurred commonly but was not clinically significant and resolved with prophylactic allopurinol; other adverse events included transient anaemia and/or thrombocytopenia (not clinically significant), renal impairment and transient infusion-related hypotension (clinically significant), and 210 mg/kg was the maximum tolerated single dose.5 In the Bosselaar study (2011, ten healthy participants), AICAR raised heart rate and lowered blood pressure compared with placebo during insulin clamps.8
Does AICAR work by mouth?
In the 1991 placebo-controlled study in healthy men (Dixon and colleagues; four on drug and two on placebo at each of four dose levels), acadesine was poorly bioavailable, less than 5%, when given orally in solution.6
References
- PubMed. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. 1995. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00872001: The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED). 2012. clinicaltrials.gov
- European Medicines Agency. EU/3/05/280 - orphan designation for treatment of B-cell chronic lymphocytic leukaemia | European Medicines Agency (EMA). ema.europa.eu
- PMC. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. 2009. pmc.ncbi.nlm.nih.gov
- PMC. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. 2012. pmc.ncbi.nlm.nih.gov
- PubMed. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. 1991. pubmed.ncbi.nlm.nih.gov
- PubMed. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. 2012. pubmed.ncbi.nlm.nih.gov
- PubMed. Intravenous AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local metabolic effect. 2011. pubmed.ncbi.nlm.nih.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org